-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the influence of various factors such as population aging, life>
.
It is worth noting that while the ophthalmology medical market continues to expand, more and more companies are also increasing their layout in this field, trying to grab a piece of the pie
.
Recently, Gaush Meditech Ltd (hereinafter referred to as "Gaoshi Medical") submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and Haitong International as their joint sponsors
.
According to data, Gaoshi Medical is a full-line solution provider for ophthalmic medical equipment.
Its product portfolio covers seven major ophthalmology subspecialties, including fundus disease, cataracts, refractive errors, glaucoma, ocular surface diseases, optometry and children's ophthalmology.
The category of medical devices also includes products distributed by brand partners and self-owned products developed and manufactured
.
At present, Gaoshi Medical has provided one-stop professional ophthalmic medical device solutions for more than 4,000 end customers in China (including more than 1,000 tertiary hospitals and serving all provincial administrative regions in China), including ophthalmic diagnostic equipment, Surgical and therapeutic equipment and consumables, and provide after-sales technical services
.
In addition to Gaoshi Medical, in July this year, Chaoju Ophthalmology was also listed on the Hong Kong Stock Exchange.
The company plans to sell approximately 171 million shares globally, with the Hong Kong public offering accounting for 10% and the international offering accounting for 90%
.
It is worth mentioning that, on the first day of listing, Chaoju Ophthalmology once rose nearly 19% at the beginning of the market to 12.
6 Hong Kong dollars, with a market value of 8.
6 billion Hong Kong dollars
.
Industry analysts believe that as the domestic ophthalmic drug market has become more and more promising in recent years, relevant companies are accelerating market expansion
.
In addition to listing, a large number of local pharmaceutical companies are also expanding their R&D investment and exploring breakthrough new ophthalmic drugs and therapies
.
For example, JiMu Biotech announced the signing of an exclusive license agreement with ActualEyes.
The former will be responsible for the development and commercialization of a new type of cell injection therapy AE-101 in Greater China (Mainland China, Hong Kong, Macau and Taiwan) and South Korea.
, Used to treat corneal endothelial dysfunction
.
According to the terms of the agreement, ActualEyes is expected to receive more than 35 million U.
S.
dollars in payments, including advance payments, R&D milestone payments, and sales tiered commissions
.
In addition, earlier, the Chinese innovative ophthalmology company Weishou Bio has also announced that it has completed a 300 million yuan D round of financing
.
The funds will be used to support the clinical development of a number of innovative ophthalmic drug products, including the ongoing dry eye disease project VVN001 Phase II US clinical study
.
In this regard, the analysis believes that with the intensification of aging, changes in living habits, and faster pace of life, the number of patients with various ophthalmic diseases will continue to increase, and the ophthalmic medical market will continue to expand
.
It is estimated that the domestic ophthalmic medical device market will grow to 37.
5 billion yuan in 2021, with a compound annual growth rate of 18.
5%
.
In this context, the listing and financing of related companies may become the norm
.
But it should be noted that the ophthalmology track is not easy to cultivate.
It is a field with high barriers to entry and strong first-mover effect
.
It is understood that recently, due to successive setbacks in the traditional core ophthalmology circuit, pharmaceutical companies have switched to the tens of billions of depression drug market
.
Specifically, Kanghong Pharmaceutical recently issued an announcement stating that the company's vothiaxetine hydrobromide tablets were officially approved for production on November 5, 2021 and obtained the "Drug Registration Certificate
.
" It is understood that the original research of vothiaxetine hydrobromide tablets was jointly developed by Denmark's Lundbeck and Takeda, and was approved to officially enter China in 2017 for the treatment of adult depression
.
In this regard, the industry believes that domestic companies must continue to innovate and rely on high-tech to compete with foreign companies to meet the unmet clinical needs of the domestic ophthalmology market
.
In this process, due to the current development trend, the homogeneity of relatively low-end vision care products is gradually becoming serious, and it is difficult to become a competitive advantage of various companies.
Therefore, the future competition in the ophthalmic medical field may be mainly reflected in the high-tech industry.
Technology advantage in the high-end market
.
.
It is worth noting that while the ophthalmology medical market continues to expand, more and more companies are also increasing their layout in this field, trying to grab a piece of the pie
.
Recently, Gaush Meditech Ltd (hereinafter referred to as "Gaoshi Medical") submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and Haitong International as their joint sponsors
.
According to data, Gaoshi Medical is a full-line solution provider for ophthalmic medical equipment.
Its product portfolio covers seven major ophthalmology subspecialties, including fundus disease, cataracts, refractive errors, glaucoma, ocular surface diseases, optometry and children's ophthalmology.
The category of medical devices also includes products distributed by brand partners and self-owned products developed and manufactured
.
At present, Gaoshi Medical has provided one-stop professional ophthalmic medical device solutions for more than 4,000 end customers in China (including more than 1,000 tertiary hospitals and serving all provincial administrative regions in China), including ophthalmic diagnostic equipment, Surgical and therapeutic equipment and consumables, and provide after-sales technical services
.
In addition to Gaoshi Medical, in July this year, Chaoju Ophthalmology was also listed on the Hong Kong Stock Exchange.
The company plans to sell approximately 171 million shares globally, with the Hong Kong public offering accounting for 10% and the international offering accounting for 90%
.
It is worth mentioning that, on the first day of listing, Chaoju Ophthalmology once rose nearly 19% at the beginning of the market to 12.
6 Hong Kong dollars, with a market value of 8.
6 billion Hong Kong dollars
.
Industry analysts believe that as the domestic ophthalmic drug market has become more and more promising in recent years, relevant companies are accelerating market expansion
.
In addition to listing, a large number of local pharmaceutical companies are also expanding their R&D investment and exploring breakthrough new ophthalmic drugs and therapies
.
For example, JiMu Biotech announced the signing of an exclusive license agreement with ActualEyes.
The former will be responsible for the development and commercialization of a new type of cell injection therapy AE-101 in Greater China (Mainland China, Hong Kong, Macau and Taiwan) and South Korea.
, Used to treat corneal endothelial dysfunction
.
According to the terms of the agreement, ActualEyes is expected to receive more than 35 million U.
S.
dollars in payments, including advance payments, R&D milestone payments, and sales tiered commissions
.
In addition, earlier, the Chinese innovative ophthalmology company Weishou Bio has also announced that it has completed a 300 million yuan D round of financing
.
The funds will be used to support the clinical development of a number of innovative ophthalmic drug products, including the ongoing dry eye disease project VVN001 Phase II US clinical study
.
In this regard, the analysis believes that with the intensification of aging, changes in living habits, and faster pace of life, the number of patients with various ophthalmic diseases will continue to increase, and the ophthalmic medical market will continue to expand
.
It is estimated that the domestic ophthalmic medical device market will grow to 37.
5 billion yuan in 2021, with a compound annual growth rate of 18.
5%
.
In this context, the listing and financing of related companies may become the norm
.
But it should be noted that the ophthalmology track is not easy to cultivate.
It is a field with high barriers to entry and strong first-mover effect
.
It is understood that recently, due to successive setbacks in the traditional core ophthalmology circuit, pharmaceutical companies have switched to the tens of billions of depression drug market
.
Specifically, Kanghong Pharmaceutical recently issued an announcement stating that the company's vothiaxetine hydrobromide tablets were officially approved for production on November 5, 2021 and obtained the "Drug Registration Certificate
.
" It is understood that the original research of vothiaxetine hydrobromide tablets was jointly developed by Denmark's Lundbeck and Takeda, and was approved to officially enter China in 2017 for the treatment of adult depression
.
In this regard, the industry believes that domestic companies must continue to innovate and rely on high-tech to compete with foreign companies to meet the unmet clinical needs of the domestic ophthalmology market
.
In this process, due to the current development trend, the homogeneity of relatively low-end vision care products is gradually becoming serious, and it is difficult to become a competitive advantage of various companies.
Therefore, the future competition in the ophthalmic medical field may be mainly reflected in the high-tech industry.
Technology advantage in the high-end market
.
